Detalhe da pesquisa
1.
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Lancet Oncol
; 20(10): 1395-1408, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31422028
2.
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
J Clin Oncol
; 39(7): 723-733, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33449799